Results 151 to 160 of about 1,675 (195)
Some of the next articles are maybe not open access.
PTLD in Intestinal Transplant Recipients
2021Post-transplant lymphoproliferative disorder (PTLD), a lethal disease, is a direct consequence of modulation of recipient’s immune system by immunosuppression. Intestinal transplant recipients are at particular risk given the intensity of necessary immunosuppression and the volume of transplanted lymphoid tissue.
Ajai Khanna, George V. Mazariegos
openaire +1 more source
PTLD After Heart Transplantation
2021PTLD in adult and childhood heart transplant recipients remains poorly understood but is associated with double the mortality compared to recipients without PTLD. PTLD makes up the minority of malignancies (1%) in adults post-heart transplant, and, other than younger age, there is a clear paucity of data in the literature regarding risk factors for ...
Anne I. Dipchand, Michael McDonald
openaire +1 more source
2010
Poor prognostic factors in the traditional non-Hodgkin's lymphomas (NHL), such as poor performance status, multifocal disease, and increased age, are also poor prognostic factors in posttransplant lymphoproliferative disorders (PTLD). Rituximab has proven efficacy in CD-20 positive PTLD and has altered the management and prognosis of this disease.
Tapan Maniar, Donald Tsai
openaire +1 more source
Poor prognostic factors in the traditional non-Hodgkin's lymphomas (NHL), such as poor performance status, multifocal disease, and increased age, are also poor prognostic factors in posttransplant lymphoproliferative disorders (PTLD). Rituximab has proven efficacy in CD-20 positive PTLD and has altered the management and prognosis of this disease.
Tapan Maniar, Donald Tsai
openaire +1 more source
Biomarkers for PTLD diagnosis and therapies
Pediatric Nephrology, 2019Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of lymphoproliferative disorders and is a serious complication of pediatric transplantation. The majority of PTLD are associated with Epstein Barr virus (EBV) and the characteristic EBV+ B cell lymphomas are the leading post-transplant malignancy in children.
openaire +2 more sources
2021
No therapies for PTLD after solid organ transplantation are based on data from randomized clinical trials, but available phase II trial data help guide therapeutic decision making. Reduction or cessation of immunosuppression is performed at the time of diagnosis in almost all patients.
Ralf Ulrich Trappe, Steven A. Webber
openaire +1 more source
No therapies for PTLD after solid organ transplantation are based on data from randomized clinical trials, but available phase II trial data help guide therapeutic decision making. Reduction or cessation of immunosuppression is performed at the time of diagnosis in almost all patients.
Ralf Ulrich Trappe, Steven A. Webber
openaire +1 more source
EBV Biology in the Pathogenesis of PTLD
2021Epstein-Barr virus (EBV) is a ubiquitous, yet perplexing, gammaherpesvirus. Primary infection with EBV can have widely diverse outcomes ranging from asymptomatic infection to self-resolving infectious mononucleosis, to the development of EBV-associated malignancies including Burkitt lymphoma, Hodgkin’s disease, nasopharyngeal carcinoma, and B cell ...
openaire +1 more source
2021
Post-transplant lymphoproliferative disorders (PTLDs) are life-threatening complications after hematopoietic stem cell transplantation (HSCT), often associated to Epstein-Barr virus (EBV) infection. Rituximab, reduction of immunosuppression, and EBV-specific cytotoxic T-lymphocyte (CTL) therapy are recommended as first-line therapy, while unselected ...
Patrizia Comoli, Jan Styczynski
openaire +1 more source
Post-transplant lymphoproliferative disorders (PTLDs) are life-threatening complications after hematopoietic stem cell transplantation (HSCT), often associated to Epstein-Barr virus (EBV) infection. Rituximab, reduction of immunosuppression, and EBV-specific cytotoxic T-lymphocyte (CTL) therapy are recommended as first-line therapy, while unselected ...
Patrizia Comoli, Jan Styczynski
openaire +1 more source
2010
Several different types of risk factors (host, infectious, transplant immunosuppression) are associated with posttransplant lymphoproliferative disorders (PTLD) development Epstein—Barr virus (EBV) infection is the single most important risk factor PTLD is a significant cause of earlier graft loss and added ...
openaire +1 more source
Several different types of risk factors (host, infectious, transplant immunosuppression) are associated with posttransplant lymphoproliferative disorders (PTLD) development Epstein—Barr virus (EBV) infection is the single most important risk factor PTLD is a significant cause of earlier graft loss and added ...
openaire +1 more source
Host Genetic Mutations and Expression Analyses in PTLD
2021This chapter focusses upon the host genetic lesions seen in PTLD, an area that has been relatively under-investigated compared to viral oncogenesis. Observations include mutations in DNA mismatch repair mechanisms, aberrant somatic hypermutation and mutations of proto-oncogenes.
Lees, Charlotte, Gandhi, Maher K.
openaire +2 more sources